“31-Gene Expression Profile Testing Survival Benefit in a Population-based Analysis of Cutaneous Melanoma Patients ≥65 Years of Age”, J of Skin, vol. 6, no. 2, p. s24, Mar. 2022, doi: 10.25251/skin.6.supp.24.